natgillin/translations-raw huggingface dataset:
After removing NovoMix 30 FlexPen from the refrigerator, it is recommended to allow NovoMix 30 FlexPen to reach room temperature before resuspending the insulin as instructed for first time use.
Nakon što se NovoMix 30 FlexPen izvadi iz hladnjaka, preporučuje se pustiti NovoMix 30 FlexPen da dosegne sobnu temperaturu prije resuspendiranja inzulina prema uputama za prvu primjenu.
After removing NovoMix 30 Penfill from the refrigerator, it is recommended to allow NovoMix 30 Penfill to reach room temperature before resuspending the insulin as instructed for first time use.
Nakon što se NovoMix 30 Penfill izvadi iz hladnjaka, preporučuje se pustiti NovoMix 30 Penfill da dosegne sobnu temperaturu prije resuspendiranja inzulina prema uputama za prvu primjenu.
After removing NovoMix 50 FlexPen from the refrigerator, it is recommended to allow NovoMix 50 FlexPen to reach room temperature before resuspending the insulin as instructed for first time use.
Nakon što se NovoMix 50 FlexPen izvadi iz hladnjaka, preporučuje se pustiti NovoMix 50 FlexPen da dosegne sobnu temperaturu prije resuspendiranja inzulina prema uputama za prvu primjenu.
After removing NovoMix 50 Penfill from the refrigerator, it is recommended to allow NovoMix 50 Penfill to reach room temperature before resuspending the insulin as instructed for first time use.
Nakon što se NovoMix 50 Penfill izvadi iz hladnjaka, preporučuje se pustiti NovoMix 50 Penfill da dosegne sobnu temperaturu prije resuspendiranja inzulina prema uputama za prvu primjenu.
After removing NovoMix 70 FlexPen from the refrigerator, it is recommended to allow NovoMix 70 FlexPen to reach room temperature before resuspending the insulin as instructed for first time use.
Nakon što se NovoMix 70 FlexPen izvadi iz hladnjaka, preporučuje se pustiti NovoMix 70 FlexPen da dosegne sobnu temperaturu prije resuspendiranja inzulina prema uputama za prvu primjenu.
After removing NovoMix 70 Penfill from the refrigerator, it is recommended to allow NovoMix 70 Penfill to reach room temperature before resuspending the insulin as instructed for first time use.
Nakon što se NovoMix 70 Penfill izvadi iz hladnjaka, preporučuje se pustiti NovoMix 70 Penfill da dosegne sobnu temperaturu prije resuspendiranja inzulina prema uputama za prvu primjenu.
After removing one syringe from the blister pack the solution should be checked to ensure that it is clear, colourless and practically free from visible particles.
Nakon vađenja štrcaljke iz blister pakiranja potrebno je provjeriti je li tekućina bistra, bezbojna i praktički bez vidljivih čestica.
After removing Protaphane FlexPen from the refrigerator, it is recommended to allow the Protaphane FlexPen to reach room temperature before resuspending the insulin as instructed for first time use.
Nakon što se Protaphane FlexPen izvadi iz hladnjaka, preporučuje se pustiti ga da dosegne sobnu temperaturu prije resuspendiranja inzulina prema uputama za prvu uporabu.
After removing Protaphane InnoLet from the refrigerator, it is recommended to allow the Protaphane InnoLet to reach room temperature before resuspending the insulin as instructed for first time use.
Nakon što se Protaphane InnoLet izvadi iz hladnjaka, preporučuje se pustiti ga da dosegne sobnu temperaturu prije resuspendiranja inzulina prema uputama za prvu uporabu.
After removing Protaphane Penfill from the refrigerator, it is recommended to allow the Protaphane Penfill to reach room temperature before resuspending the insulin as instructed for first time use.
Nakon što se Protaphane Penfill izvadi iz hladnjaka, preporučuje se pustiti ga da dosegne sobnu temperaturu prije resuspendiranja inzulina prema uputama za prvu uporabu.
After removing Protaphane vial from the refrigerator, it is recommended to allow the Protaphane vial to reach room temperature before resuspending the insulin as instructed for first time use.
Nakon što se Protaphane bočica izvadi iz hladnjaka preporučuje se pustiti je da dosegne sobnu temperaturu prije resuspendiranja inzulina prema uputama za prvu uporabu.
After removing the ampoule(s), the remaining ampoules should be put back immediately into the canister in the liquid nitrogen container.
Nakon izdvajanja ampule, ostale ampule odmah vratiti u kontejner s tekućim dušikom.
After removing the cap the injection must be started within 5 minutes, to prevent the medicine from drying out and blocking the needle.
Kada se skine zatvarač, primjena injekcije mora započeti unutar 5 minuta, kako bi se spriječilo sušenje lijeka te začepljenje igle.
After removing the needle from the syringe, the syringe should be attached to the filter by opening the filter luer connector cap (Figure 1).
Nakon što se sa štrcaljke ukloni igla, štrcaljku treba učvrstiti na filtar otvaranjem luer spojnice na filtru (slika 1).
After removing the pen cap, the appearance of insulin should also be checked: the insulin solution must be clear, colourless, with no solid particles visible, and must have a water-like consistency.
Nakon što skinete zatvarač brizgalice, treba provjeriti i izgled inzulina: otopina inzulina mora biti bistra, bezbojna, vodenaste konzistencije i bez vidljivih krutih čestica.
After removing the pen cap, the appearance of the insulin should also be checked:
Nakon što skinete zatvarač brizgalice, treba provjeriti i izgled inzulina:
After removing the pen cap, the label on the pen and the insulin reservoir should be checked to make sure it contains the correct insulin.
Nakon što skinete zatvarač brizgalice, treba provjeriti oznaku na brizgalici i spremniku inzulina kako biste bili sigurni da se radi o ispravnoj vrsti inzulina.
After removing the pre-filled pen from the refrigerator the pre-filled pen should be allowed to reach room temperature by waiting 30 minutes, before injecting ORENCIA.
Nakon što se napunjena brizgalica izvadi iz hladnjaka, treba pričekati 30 minuta da se napunjena brizgalica zagrije na sobnu temperaturu prije injiciranja lijeka ORENCIA.
After removing the pre-filled syringe from the refrigerator the pre-filled syringe should be allowed to reach room temperature (18°C to 28C°) by waiting for 25 to 30 minutes, before injecting RoActemra .
Kada se napunjena štrcaljka izvadi iz hladnjaka, treba pričekati najmanje 25-30 minuta prije injekcije lijeka RoActemra da se napunjena štrcaljka ugrije na sobnu temperaturu (18°C do 28°C).
After removing the pre-filled syringe from the refrigerator the pre-filled syringe should be allowed to reach room temperature by waiting 30 minutes, before injecting ORENCIA.
Nakon što se napunjena štrcaljka izvadi iz hladnjaka, treba pričekati 30 minuta da se napunjena štrcaljka zagrije na sobnu temperaturu prije injiciranja lijeka ORENCIA.
After repeat dosing, slight accumulation occurred, but a steady state was achieved within 5 days.
Nakon ponovljene doze događa se blaga akumulacija ali se ravnotežno stanje postiže unutar pet dana.
After repeated administration with 20 mg esomeprazole once daily for five days, mean peak acid output after pentagastrin stimulation is decreased 90% when measured 6-7 hours after dosing on day five.
Nakon višekratne primjene 20 mg esomeprazola jednom na dan tijekom pet dana, srednje vršne vrijednosti lučenja kiseline nakon stimulacije pentagastrinom smanjile su se za 90%, mjereno petoga dana 6-7 sati nakon uzimanja doze.
After repeated administrations of Pixuvri at doses as low as 0,1 mg/kg/day, a dose-dependent testicular atrophy was detected in the dogs.
Nakon ponovljenih primjena Pixuvria već u niskim dozama od 0,1 mg/kg/dan, zabilježena je atrofija testisa u pasa, ovisno o dozi.
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min) compared inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Nakon ponovljenih doza od 75 mg klopidogrela dnevno, inhibicija ADP-om inducirane agregacije trombocita bila je niža (25%) u ispitanika s teško narušenom funkcijom bubrega (klirens kreatinina od 5 do 15 ml/min) u usporedbi sa zdravim ispitanicima, iako je produljenje vremena krvarenja bilo slično onom zabilježenom u zdravih bolesnika koji su primali 75 mg klopidogrela dnevno.
After repeated dosing 0.25 mg/day steady-state levels of approximately 0.6 ng/mL were reached within 2 to 3 days.
0,25 mg/dan, razine u stanju dinamičke ravnoteže od približno 0,6 ng/ml postignute su unutar 2-3 dana.
After repeated once-daily administration of 40 mg esomeprazole, the mean area under the plasma concentration-time curve was approximately 100% higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers).
Nakon višekratne primjene doze od 40 mg esomeprazola jedanput na dan srednja vrijednost površina ispod krivulje bila je otprilike 100% veća u slabih metabolizatora nego u ispitanika u kojih je enzim CYP2C19 funkcionalan (dobri metabolizatori).
After repeated oral administration, R-diastereomer of telaprevir (30-fold less active), pyrazinoic acid, and a metabolite that underwent reduction at the α-ketoamide bond of telaprevir (not active) were found to be the predominant metabolites of telaprevir.
Nakon ponovne peroralne primjene pronađeni su glavni metaboliti telaprevira, R-diastereomer telaprevira (30 puta slabijeg djelovanja), pirazinoična kiselina i metabolit koji je prošao redukciju na α-ketoamidnoj vezi telaprevira (bez djelovanja).
After repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed.
Nakon ponovljene oralne doze od 75 mg dnevno, klopidogrel se brzo apsorbira.
After repeated subcutaneous administration of 40 mg once daily and 1.5 mg/kg once daily regimens in healthy volunteers, the steady-state is reached on day 2 with an average exposure ratio about 15% higher than after a single dose.
Nakon ponavljane supkutane primjene 40 mg jedanput na dan i režima doziranja od 1,5 mg/g jedanput na dan u zdravih dragovoljaca, stanje dinamičke ravnoteže je postignuto 2. dana s prosječnim omjerom izloženosti od približno 15% više nego pri jednokratnom doziranju.
After repeated subcutaneous administration of 40 mg once daily and 1.5 mg/kg once daily regimens in healthy volunteers, the steady-state is reached on day 2 with an average exposure ratio about 15% higher than after a single dose.
Nakon ponavljane supkutane primjene 40 mg jedanput na dan i režima doziranja od 1,5 mg/kg jedanput na dan u zdravih dragovoljaca, stanje dinamičke ravnoteže je postignuto 2. dana s prosječnim omjerom izloženosti od približno 15 % više nego pri jednokratnom doziranju.
After repeated subcutaneous administration of 40 mg once daily and 1.5 mg/kg once daily regimens in healthy volunteers, the steady-state is reached on day 2 with an average exposure ratio about 15% higher than after a single dose.
Nakon ponavljane supkutane primjene 40 mg jedanput na dan i režima doziranja od 1,5 mg/kg jedanput na dan u zdravih dragovoljaca, stanje dinamičke ravnoteže je postignuto 2. dana s prosječnim omjerom izloženosti od približno 15% više nego pri jednokratnom doziranju.
After repeated subcutaneous administration of the 1 mg/kg twice daily regimen, the steady-state is reached from day 3 to 4 with mean exposure about 65% higher than after a single dose and mean peak and trough levels of about 1.2 and 0.52 IU/mL, respectively.
Nakon ponavljane supkutane primjene u režimu doziranja od 1 mg/kg dva puta dnevno, stanje dinamičke ravnoteže postignuto je od 3. do 4. dana sa srednjom izloženošću od približno 65 % višom nego nakon jednokratnog doziranja, te srednjom vršnom vrijednosti i najnižim razinama od otprilike 1,2 i 0,52 IU/ml.
After repeated subcutaneous administration of the 1 mg/kg twice daily regimen, the steady-state is reached from day 3 to 4 with mean exposure about 65% higher than after a single dose and mean peak and trough levels of about 1.2 and 0.52 IU/mL, respectively.
Nakon ponavljane supkutane primjene u režimu doziranja od 1 mg/kg dva puta dnevno, stanje dinamičke ravnoteže postignuto je od 3. do 4. dana sa srednjom izloženošću od približno 65% višom nego nakon jednokratnog doziranja, te srednjom vršnom vrijednosti i najnižim razinama od otprilike 1,2 i 0,52 IU/ml.
After repeated subcutaneous administration of the 1 mg/kg twice daily regimen, the steady-state is reached from day 3 to 4 with mean exposure about 65% higher than after a single dose and mean peak and trough levels of about 1.2 and 0.52 IU/mL, respectively.
Nakon ponavljane supkutane primjene u režimu doziranja od 1 mg/kg dva puta dnevno, stanje dinamičke ravnoteže postignuto je od 3.doi 4. dana sa srednjom izloženošću od približno 65% višom nego nakon jednokratnog doziranja, te srednjom vršnom vrijednosti i najnižimrazinama od otprilike 1,2 i 0,52 IU/ml.
After repeated treatment with Nonafact, patients should be monitored for the development of neutralising antibodies (inhibitors) that should be quantified in Bethesda Units (BU) using appropriate biological testing.
Nakon ponavljanih liječenja lijekom Nonafact potrebno je pratiti razvoj neutralizirajućih antitijela (inhibitora) kod pacijenta, koje je odgovarajućim biološkim testovima potrebno izraziti u Bethesda jedinicama (BU).
After repeated, once daily subcutaneous doses of 1.5 mg/kg, mean AUC of anti-Xa activity is marginally higher at steady state in obese healthy volunteers (BMI 30-48 kg/m2) compared to non-obese control subjects, while Amax is not increased.
Nakon ponavljane supkutane doze od 1,5 mg/kg jedanput na dan, srednja vrijednost AUC anti-Xa aktivnosti granično je veća u stanju dinamičke ravnoteže u pretilih zdravih dragovoljaca (ITM 30- 48 kg/m2) u usporedbi s ispitanicima normalne tjelesne težine u kontrolnoj skupini, dok Amax nije povećan.
After repeated, once daily subcutaneous doses of 1.5 mg/kg, mean AUC of anti-Xa activity is marginally higher at steady state in obese healthy volunteers (BMI 30-48 kg/m2) compared to non-obese control subjects, while Amax is not increased.
Nakon ponavljane supkutane doze od 1,5 mg/kg jedanput na dan, srednja vrijednost AUC-a anti-Xa aktivnosti granično je veća u stanju dinamičke ravnoteže u pretilih zdravih dragovoljaca (ITM 30- 48 kg/m2) u usporedbi s ispitanicima normalne tjelesne težine u kontrolnoj skupini, dok Amax nije povećan.
After repetitive yearly injections the safety profile of IDflu is similar to the previous injections.
Nakon ponavljane sezonske primjene, sigurnosni profil IDflu-a sličan je onom dobivenom pri prijašnjim cijepljenjima.
After repetitive yearly injections the safety profile of INTANZA is similar to the previous injections.
Nakon ponavljane sezonske primjene, sigurnosni profil cjepiva INTANZA sličan je onom dobivenom pri prijašnjim cijepljenjima.
After resolution
Po povlačenju simptoma
After resolution, a functional assessment should be performed prior to resuming treatment with dasatinib.
Nakon povlačenja tih znakova i simptoma, a prije nastavka liječenja dasatinibom, mora se izvršiti procjena srčane funkcije.
After resuspending, complete all of the following stages of injection without delay.
Nakon što ste izmiješali inzulin, bez odgađanja dovršite sve preostale korake injiciranja.
After screwing the push rod into the syringe piston, it is important to turn the push rod an additional ½ turn so that the grey piston rotates freely
Nakon što ste navinuli klip u čep klipa koji je ugrađen u štrcaljku, važno je da okrenete klip još dodatnih pola kruga tako da se sivi ugrađeni čep klipa može slobodno okretati.
After second and third vaccination a rectal temperature increase of up to 1.3 °C and 2.8 °C respectively may occur very commonly one day after the injection and then rectal temperatures return to normal values.
Nakon drugog i trećeg cijepljenja, vrlo često može doći do povišenja rektalne temperature od 1,3 °C, odnosno 2,8 °C, jedan dan nakon cijepljenja, a zatim se rektalna temperatura vraća na normalne vrijednosti.
After second and third vaccination a rectal temperature increase of up to 1.3°C and 2.8°C respectively may occur very commonly one day after the injection and then rectal temperatures return to normal values.
Nakon drugog i trećeg cijepljenja može vrlo često doći do povišenja rektalne temperature od 1,3 °C, odnosno 2,8 °C jedan dan nakon cijepljenja, a zatim se rektalna temperatura vraća na normalne vrijednosti.
After section 6 of this leaflet there are Instructions For Use giving you step-by-step instructions on how to mix your medicine and how to inject it.
Nakon dijela 6. ove Upute navode se Upute za uporabu, u kojima se korak po korak objašnjava kako pomiješati lijek i kako ga injicirati.
After Simparica is given its activity against ticks and fleas lasts for for at least 5 weeks.
Nakon primjene VMP-a Simparica, VMP djeluje protiv krpelja i buha najmanje 5 tjedana.
After single administration of a 15 micrograms sufentanil sublingual tablet, mean terminal phase half- lives in the range of 6 to 10 hours have been observed.
Nakon jednokratne primjene sufentanil sublingvalne tablete od 15 mikrograma, uočeni su srednji poluvijekovi terminalne faze u rasponu od 6 do 10 sati.
After single dose administration in the dose range of 75 to 600 mg, a 2-fold increase in dose results in a ~2.3 and 2.6- fold increase in AUC and Cmax, respectively.
Nakon primjene jednokratne doze u rasponu doza od 75 do 600 mg, 2 puta povećanje doze rezultira ~2,3-, odnosno 2,6 puta povećanjem AUC-a, odnosno Cmax-a.
After single dose oral administration of 14C-rilpivirine, on average 85% and 6.1% of the radioactivity could be retrieved in faeces and urine, respectively.
Nakon peroralne primjene jedne doze 14C-rilpivirina, u prosjeku se 85% radioaktivnosti moglo otkriti u stolici a 6,1% u mokraći.
After single dose oral administration of 14C-rilpivirine, on average 85% and 6.1% of the radioactivity could be retrieved in faeces and urine, respectively.
Nakon peroralne primjene jednostruke doze 14C-rilpivirina, moglo se otkriti u prosjeku 85% radioaktivnosti u stolici i 6,1% u mokraći.
After single doses food increases the bioavailability (AUC) of rufinamide by approximately 34% and the peak plasma concentration by 56%.
Nakon jednokratne doze rufinamida hrana povećava njegovu bioraspoloživost (AUC) za približno 34%, a njegovu vršnu koncentraciju u plazmi za 56%.
After single doses food increases the bioavailability (AUC) of rufinamide by approximately 34% and the peak plasma concentration by 56%.
Nakon jednokratne doze rufinamida, hrana povećava njegovu bioraspoloživost (AUC) za približno 34%, a njegovu vršnu koncentraciju u plazmi za 56%.
After single oral administration of ceritinib in patients, plasma exposure to ceritinib, as represented by Cmax and AUClast, increased dose-proportionally over the 50 to 750 mg dose range.
Nakon jednokratne peroralne primjene ceritiniba u bolesnika, izloženost plazme ceritinibu, predstavljena vrijednostima Cmax i AUClast, povećala se proporcionalno dozi u rasponu doze od 50 do 750 mg.
After single oral doses using buffered solution mean maximum palonosetron concentrations (Cmax) and area under the concentration-time curve (AUC0-∞) were dose proportional over the dose range of 3.0 to 80 µg/kg in healthy subjects.
U zdravih ispitanika, nakon jednokratnih oralnih doza uz korištenje puferirane otopine, prosječne maksimalne koncentracije palonosetrona (Cmax) i površina ispod krivulje koncentracija- vrijeme (AUC0-∞) bile se proporcionalne dozi u rasponu doze od 3,0 do 80 µg/kg.
After six months of treatment, 45% of patients taking RoActemra in combination with methotrexate (130 out of 290) and 39% of patients taking RoActemra on its own (113 out of 292) achieved remission (did not show symptoms of the disease), compared with 15% of those taking placebo plus methotrexate (43 out of 287).
Nakon šest mjeseci terapije, u 45 % bolesnika (130 od 290) koji su primali lijek RoActemra u kombinaciji s metotreksatom i 39 % bolesnika (113 od 292) koji su primali lijek RoActemra kao monoterapiju došlo je do remisije (nisu pokazivali simptome bolesti), u usporedbi s 15 % bolesnika (43 od 287) koji su primali placebo u kombinaciji s metotreksatom.
After stabilisation of patient’s blood glucose adjustment of the dose should be considered (see sections 4.8 and 4.9).
Nakon što u bolesnika dođe do stabilizacije glikemije treba razmotriti prilagodbu doze (vidjeti dijelove 4.8 i 4.9).
After stabilisation of the patient’s blood glucose, adjustment of the dose should be considered (see sections 4.2, 4.8 and 4.9).
Nakon što se bolesnikova razina glukoze u krvi stabilizira, treba razmotriti prilagodbu doze (vidjeti dijelove 4.2, 4.8 i 4.9).
After stabilisation of the patient’s blood glucose, adjustment of the dose should be considered (see sections 4.8 and 4.9).
Nakon što se bolesnikova razina glukoze u krvi stabilizira, treba razmotriti prilagodbu doze (vidjeti dijelove 4.8. i 4.9).
After stabilisation of the patient’s blood glucose, adjustment of the dose should be considered (see sections 4.8 and 4.9).
Nakon što u bolesnika dođe do stabilizacije glikemije treba razmotriti prilagodbu doze (vidjeti dijelove 4.8 i 4.9).
After stabilisation of the patient’s blood glucose, adjustment of the dose should be considered (see sections 4.8 and 4.9).
Nakon što u bolesnika dođe do stabilizacije glikemije, treba razmotriti prilagodbu doze (vidjeti dijelove 4.8 i 4.9).
After starting somatropin treatment some patients may need to start thyroid hormone replacement.
Pojedini bolesnici nakon započinjanja liječenja somatropinom moraju započeti nadomjesnu terapiju hormonima štitnjače.
After steady state is reached, serum calcium concentrations remain constant over the dosing interval.
Nakon što se uspostavi ravnoteža, serumska koncentracija kalcija ostaje stalna kroz interval primjene.
After stopping Hepsera tell your doctor immediately about any new, unusual or worsening symptoms that you notice after stopping treatment.
Nakon što prestanete uzimati Hepseru odmah obavijestite svog liječnika o bilo kojim novim, neuobičajenim ili pogoršanim simptomima koje ste primijetili nakon prekida liječenja.
After stopping this medicine you must allow 14 days before taking any of these medicines.
Nakon prestanka uzimanja ovog lijeka, morate pričekati 14 dana prije uzimanja bilo kojeg od ovih lijekova.
After stopping this medicine, you must allow 14 days before taking any of these medicines.
Nakon prestanka uzimanja ovog lijeka morate pričekati 14 dana prije uzimanja bilo kojeg od ovih lijekova.
After stopping this medicine, you must allow 14 days before taking any of these medicines.
Nakon prestanka uzimanja ovog lijeka, morate pričekati 14 dana prije uzimanja bilo kojeg od ovih lijekova.
After stopping treatment with Kivexa for reasons of a suspected HSR, Kivexa or any other medicinal product containing abacavir (e.g.
Nakon prekida liječenja lijekom Kivexa zbog suspektne reakcije preosjetljivosti, nikada se ne smije ponovno započeti liječenje lijekom Kivexa niti bilo kojim drugim lijekom koji sadrži abakavir (npr.
After stopping treatment with Triumeq for reasons of a suspected HSR, Triumeq or any other medicinal product containing abacavir or dolutegravir must never be re-initiated.
Nakon prekida liječenja lijekom Triumeq zbog suspektne reakcije preosjetljivosti, nikada se ne smije ponovno započeti liječenje lijekom Triumeq niti bilo kojim drugim lijekom koji sadrži abakavir ili dolutegravir.
After stopping treatment with Trizivir for reasons of a suspected HSR, Trizivir or any other medicinal product containing abacavir (e.g.
Nakon prekida liječenja lijekom Trizivir zbog suspektne reakcije preosjetljivosti, nikada se ne smije ponovno započeti liječenje lijekom Trizivir niti bilo kojim drugim lijekom koji sadrži abakavir (npr.
After stopping treatment, risk may remain elevated for at least 10 years.
Nakon prekida liječenja rizik može ostati povećan najmanje 10 godina.
After storage at 2°C to 8°C, the solution should be allowed to come to room temperature for approximately 20 minutes before administration.
Nakon čuvanja na 2°C do 8°C, otopinu treba pustiti da dosegne sobnu temperaturu otprilike 20 minuta prije primjene.
After storage at room temperature, the product may not be returned to the refrigerator.
Nakon čuvanja na sobnoj temperaturi lijek se ne smije vratiti u hladnjak.